Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Asuragen appoints BMD as exclusive distributor of Signature Oncology Products in France

Asuragen, Inc., a leader in the development of molecular diagnostics, announced today the appointment of Biomedical Diagnostics SA, a leading medical diagnostic company in Europe, as its exclusive distributor of Signature® Oncology Products in France. Asuragen’s Signature Oncology Portfolio comprises multiplex assays for the detection of mutations in solid and hematologic malignancies.

22 Mar 2010

Research roundup: Insurance crisis tough on middle class; Hospitals' profit margins on private patients up

Private-Payer Profits Can Induce Negative Medicare Margins - "Hospitals' profit margins on privately insured patients have risen dramatically in recent years, while profit margins on Medicare patients have fallen," write the authors, who all work for MedPAC.

20 Mar 2010

Community-driven approaches needed for reducing cancer-death disparities

Cancer death rates for African-Americans far exceed non-Hispanic Caucasians in the United States, and only community-driven approaches to reducing health disparities will lessen the gap, says Edward Partridge, M.D., president-elect of the American Cancer Society (ACS) National Board of Directors and director of the University of Alabama at Birmingham (UAB) Comprehensive Cancer Center.

19 Mar 2010

Studies reveal increased polyp detection rates with TER during colonoscopy

Two new studies show an increase in polyp detection rates using the Third Eye Retroscope (TER), a retrograde viewing device, during colonoscopy. The first study found that TER added to standard colonoscopy detected 13.2 percent more polyps than colonoscopy alone, including 11 percent additional adenomas (precancerous polyps). A second study examined endoscopist experience using TER and its impact on polyp detection rates, concluding that polyp detection rates improved significantly with TER.

19 Mar 2010

Researchers find some similarities between SPN and PET

Solid-pseudopapillary neoplasm (SPN) of the pancreas is relatively rare. There are some similarities between SPN and pancreatic endocrine tumor (PET), especially the non-functioning ones, in clinical and pathological manifestations.

18 Mar 2010

CCAC launches online campaign to raise colorectal screening awareness

As part of its March awareness month kick off, the Colorectal Cancer Association of Canada has launched a unique campaign to encourage Canadian men and women to show their butts online so as to raise awareness about the importance of getting screened for colorectal cancer.

18 Mar 2010

New chemotherapeutic agents for colorectal cancer: High-cost/low-value medical care

New chemotherapy agents appear associated with improvements in survival time for patients with metastastic colorectal cancer, but at substantial cost, according to a report in the March 22 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

18 Mar 2010

Genes linked to ulcerative colitis identified

A study of the human genome led by Cedars-Sinai researchers has now identified genes linked to ulcerative colitis, offering clues as to what causes the condition and potential avenues for new therapies to treat the disease.

18 Mar 2010

Research shows Caspase-1 protein plays a key role in the process of inflammation and colon cancer

Every day, our gut comes in contact with bacteria, inducing an inflammatory response that is tolerated and controlled. Sometimes the control of inflammation is lost and this can lead to inflammatory bowel disease that may predispose to colon cancer.

18 Mar 2010

New chemotherapy agents improve survival time for patients with metastatic colorectal cancer

New chemotherapy agents appear associated with improvements in survival time for patients with metastatic colorectal cancer but at substantial cost.

17 Mar 2010

Radiofrequency ablation helps prolong life of colorectal cancer patients

Approximately half of Americans living with colorectal cancer will develop liver metastases at some point during the course of their disease. Radiofrequency ablation, a minimally invasive treatment that applies heat directly in the tumor causing cancer cell death with minimal associated injury to the surrounding healthy liver, contributes to prolongation of their life by nearly three years, note researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

17 Mar 2010

Colon cancer patients often not treated with recommended level of chemotherapy

New results from a major initiative on the quality of cancer care in the United States show that patients with a common type of colon cancer -- especially older patients -- often are not treated as aggressively with chemotherapy as research shows is necessary to improve survival.

17 Mar 2010

NCCN Guidelines translated into Japanese

The NCCN Clinical Practice Guidelines in Oncology have been further recognized as the global standard in oncology with the announcement that select NCCN Guidelines™ are being translated into Japanese. The Translational Research Informatics Center Foundation for Biomedical Research and Innovation, under the supervision of the Japanese Society for Cancer of the Colon and Rectum, has translated the NCCN Guidelines for Colon Cancer and Rectal Cancer, which are now available online.

17 Mar 2010

Key cellular defect in protein synthesis can lead to cancer susceptibility

UCSF researchers have discovered that a key cellular defect that disturbs the production of proteins in human cells can lead to cancer susceptibility. The scientists also found that a new generation of inhibitory drugs offers promise in correcting this defect.

17 Mar 2010

Levels of perceived cancer risk can affect health and longevity

Mammograms, pap smears and early detection tests for prostate cancer, colorectal cancer and other malignancies are critical for catching cancer before it becomes deadly.

16 Mar 2010

Stage IV colorectal cancer: Therapy that improves overall survival over IFL/bevacizumab will earn 60% patient share

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a therapy that would improve median overall survival over IFL (bolus 5-fluorouracil, generics/leucovorin, generics/irinotecan*) plus bevacizumab (Roche/Genentech/Chugai's Avastin), would earn a 60 percent patient share in stage IV colorectal cancer, according to surveyed U.S. oncologists. In Europe, such an agent would earn a 50 percent patient share, according to surveyed European oncologists.

16 Mar 2010

Gene defects could become targets for new personalised treatments for bowel cancer

Cancer Research UK-funded scientists have discovered that the gene defects that cause some bowel cancers could become the targets for new personalised treatments. Their research is published in Cancer Cell today (Monday).

16 Mar 2010

Latest treatment options for colorectal cancer highlighted at NCCN Annual Conference

Despite statistics stating that colorectal cancer is the fourth most frequently diagnosed cancer in men and women in the United States, mortality from colon cancer has decreased slightly over the past 30 years, possibly because of earlier diagnoses through screening and better treatment modalities.

15 Mar 2010

Pro-Pharmaceuticals reports net loss applicable to common stock of $1.3M for fourth-quarter 2009

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for full year and fourth quarter, ended December 31, 2009. These results are included in the Company’s Annual Report on Form 10-K which has been filed with the SEC.

12 Mar 2010

Vermont: Only state to pass bill mandating coverage of colon cancer screening

Progress towards nationwide, state-mandated coverage of colon cancer screening according to accepted medical guidelines has slowed to a crawl as state legislators await the outcome of the health care reform debate at the federal level, a coalition of public health associations and medical professional societies reported today. With a better grade for only a single state – Vermont – 2009 marks the least improvement in a single year since the Colorectal Cancer Legislation Report Card began in 2004.

12 Mar 2010

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Asuragen appoints BMD as exclusive distributor of Signature Oncology Products in France

Research roundup: Insurance crisis tough on middle class; Hospitals' profit margins on private patients up

Community-driven approaches needed for reducing cancer-death disparities

Studies reveal increased polyp detection rates with TER during colonoscopy

Researchers find some similarities between SPN and PET

CCAC launches online campaign to raise colorectal screening awareness

New chemotherapeutic agents for colorectal cancer: High-cost/low-value medical care

Genes linked to ulcerative colitis identified

Research shows Caspase-1 protein plays a key role in the process of inflammation and colon cancer

New chemotherapy agents improve survival time for patients with metastatic colorectal cancer

Radiofrequency ablation helps prolong life of colorectal cancer patients

Colon cancer patients often not treated with recommended level of chemotherapy

NCCN Guidelines translated into Japanese

Key cellular defect in protein synthesis can lead to cancer susceptibility

Levels of perceived cancer risk can affect health and longevity

Stage IV colorectal cancer: Therapy that improves overall survival over IFL/bevacizumab will earn 60% patient share

Gene defects could become targets for new personalised treatments for bowel cancer

Latest treatment options for colorectal cancer highlighted at NCCN Annual Conference

Pro-Pharmaceuticals reports net loss applicable to common stock of $1.3M for fourth-quarter 2009

Vermont: Only state to pass bill mandating coverage of colon cancer screening

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Newsletters you may be interested in